Pharmaceutical / Drug Definition :
Alters perception of and emotional response to pain by binding with opioid receptors in brain, causing CNS depression. Also exerts antagonistic activity at opioid receptors, which reduces risk of toxicity, drug dependence, and respiratory depression.
In the United States, Butorphanol Tartrate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Butorphanol Tartrate.
FDA Label Requirements and Exceptions
FDA Import Information
Butorphanol Tartrate (Butorphanol Tartrate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Butorphanol Tartrate (Butorphanol Tartrate Suppliers)
- Processors Butorphanol Tartrate
- Repackers Butorphanol Tartrate
- Relabelers Butorphanol Tartrate
- Exporters Butorphanol Tartrate
- Importers Butorphanol Tartrate
For more information about Butorphanol Tartrate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.